Results 201 to 210 of about 47,659 (253)
Some of the next articles are maybe not open access.

Electrophysiology of phosphodiesterase inhibitors

The American Journal of Cardiology, 1989
Phosphodiesterase inhibitors appear to uniformly enhance atrioventricular node conduction, although milrinone seems to have the least effect. Except for digoxin, this effect on atrioventricular node conduction is similar to that noted with other inotropic agents.
G V, Naccarelli, R A, Goldstein
openaire   +2 more sources

Phosphodiesterase Inhibitors

open access: yes
Sylvia F. Fawzi   +3 more
openaire   +2 more sources

Xanthines and Phosphodiesterase Inhibitors

2016
Theophylline is an orally acting xanthine that has been used since 1937 for the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). However, in most treatment guidelines, xanthines have now been consigned to third-line therapy because of their narrow therapeutic window and propensity for drug-drug ...
D, Spina, C P, Page
openaire   +2 more sources

Phosphodiesterase-5 Inhibitors

2013
Nitric oxide (NO) signaling plays a key role in modulating vascular tone and remodeling in the pulmonary circulation. The guanylate cyclase/cyclic guanylate monophosphate-signaling pathway primarily mediates nitric oxide signaling. This pathway is critical in normal regulation of the pulmonary vasculature, and is an important target for therapy in ...
Barbara A, Cockrill, Aaron B, Waxman
openaire   +2 more sources

Phosphodiesterase inhibitors and lung diseases

2023
Phosphodiesterase enzymes (PDE) have long been known as regulators of cAMP and cGMP, second messengers involved in various signaling pathways and expressed in a variety of cell types implicated in respiratory diseases such as airway smooth muscle and inflammatory cells making them a key target for the treatment of lung diseases as chronic obstructive ...
Ivana, Stolfa, Clive, Page
openaire   +2 more sources

Phosphodiesterase inhibitors

2021
Cerebral ischemic diseases are among the most prevalent causes of death and the leading cause of adult disability worldwide. Although many studies have investigated the pathophysiological mechanisms involved in the cerebral ischemic injury, no effective pharmacological treatment has been established.
openaire   +1 more source

Chemotherapeutic potential of phosphodiesterase inhibitors

Current Opinion in Chemical Biology, 1998
The application of molecular cloning has revealed the phenomenal diversity and complexity of the phosphodiesterase isoenzyme family. Thus, more than 30 human phosphodiesterases are now known; all are apparently necessary for the seemingly simple task of hydrolysing the 3'-ester bond of either cyclic adenosine monophosphate or cyclic guanosine ...
M J, Perry, G A, Higgs
openaire   +2 more sources

Phosphodiesterase Inhibitors: History of Pharmacology

2011
The first pharmacological investigations of phosphodiesterase (PDE) inhibitors were developed with the clinical efficacies of drugs isolated from coffee, cacao and tea but only later their relevant ingredients were identified as xanthines that act as PDE.
Christian, Schudt   +3 more
openaire   +2 more sources

Phosphodiesterase inhibitors in airways disease

European Journal of Pharmacology, 2006
Phosphodiesterases hydrolyse intracellular cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) into inactive 5' monophosphates, and exist as 11 families. They are found in a variety of inflammatory and structural cells.
openaire   +2 more sources

[Phosphodiesterase inhibitors].

Annales de cardiologie et d'angeiologie, 1991
Phosphodiesterase III inhibitors constitute a new therapeutic group for congestive cardiac failure. They inhibit the degradation of cyclic adenosine monophosphate and increase the intracellular calcium. They have a double inotropic and vasodilator haemodynamics occurs without any increase in the myocardial effect.
A, Sarkis, M, Pornin
openaire   +1 more source

Home - About - Disclaimer - Privacy